Share Price and Basic Stock Data
Last Updated: November 3, 2025, 8:35 pm
| PEG Ratio | 6.22 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Dr Lal Pathlabs Ltd operates in the Hospitals & Medical Services industry, focusing on diagnostic services. As of October 2023, the company’s stock price was ₹3,092, with a market capitalization of ₹25,901 Cr. The company has demonstrated consistent revenue growth, recording sales of ₹2,017 Cr for the fiscal year ended March 2023, up from ₹2,087 Cr in March 2022. For the fiscal year ending March 2025, sales are expected to increase to ₹2,461 Cr, while the trailing twelve months (TTM) revenue stands at ₹2,529 Cr. Quarterly sales have shown a positive trend with a notable rise from ₹503 Cr in June 2022 to ₹601 Cr in September 2023. The company has effectively leveraged its operational efficiencies to enhance revenue, with a robust operating profit margin (OPM) that reached 30% in September 2023, compared to 23% in June 2022.
Profitability and Efficiency Metrics
Dr Lal Pathlabs reported a net profit of ₹518 Cr for the fiscal year ending March 2025, which reflects a significant increase from ₹241 Cr in March 2023. The company’s profitability metrics are impressive, showcasing a return on equity (ROE) of 24.3% and a return on capital employed (ROCE) of 28.9%. The operating profit margin (OPM) has remained stable, reported at 29% for the same period, indicating effective cost management. The interest coverage ratio (ICR) stood at an impressive 35.37x, suggesting that the company can comfortably meet its interest obligations, which is significantly higher than the typical sector range. Additionally, the cash conversion cycle (CCC) has improved to -110 days, signalling efficiency in working capital management. These metrics position Dr Lal Pathlabs favorably against its peers, highlighting its strong operational efficiency and profitability.
Balance Sheet Strength and Financial Ratios
Dr Lal Pathlabs’ balance sheet reflects solid financial health, with total assets recorded at ₹2,713 Cr as of March 2025. The company has maintained low borrowings, standing at ₹157 Cr, which indicates prudent financial management and minimal reliance on debt. Reserves have grown to ₹2,089 Cr, showcasing the company’s ability to retain earnings effectively. The debt-to-equity ratio is negligible, at 0.00, underscoring a conservative capital structure. Financial ratios such as the current ratio of 3.39 and quick ratio of 3.30 indicate strong liquidity and the ability to cover short-term liabilities. Furthermore, the price-to-book value (P/BV) ratio stood at 9.53x, which is on the higher end compared to industry norms, reflecting market confidence in the company’s growth potential. Overall, these financial indicators portray a robust and resilient balance sheet.
Shareholding Pattern and Investor Confidence
As of March 2025, Dr Lal Pathlabs had a diverse shareholding structure, with promoters holding 53.91% of the equity, a slight decline from 55.04% in December 2022. Foreign institutional investors (FIIs) accounted for 21.86%, while domestic institutional investors (DIIs) held 18.22%. The public shareholding stood at 6.07%, indicating a stable investor base. The reduction in promoter holding could raise concerns about control; however, the presence of significant institutional investment suggests robust investor confidence. The number of shareholders declined from 1,79,636 in December 2022 to 1,12,703 by March 2025, signaling a potential consolidation of ownership. This shift may reflect a strategic move by institutional investors capitalizing on the company’s growth trajectory, enhancing Dr Lal Pathlabs’ reputation within the market.
Outlook, Risks, and Final Insight
Dr Lal Pathlabs appears well-positioned for continued growth, supported by its strong profitability and operational efficiency. However, potential risks include the volatility in healthcare regulations and competition from emerging diagnostic players, which could impact market share. Additionally, the declining trend in promoter holdings may introduce governance concerns that could affect investor sentiment. Nonetheless, the company’s financial metrics, including a high ICR and low debt levels, provide a cushion against economic uncertainties. Should Dr Lal Pathlabs maintain its growth momentum and navigate industry challenges successfully, it could solidify its position as a leader in the diagnostic services sector. Investors should stay vigilant regarding market developments and regulatory changes that could influence performance in the future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dr Lal Pathlabs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.7 Cr. | 136 | 195/135 | 6.14 | 115 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.9 Cr. | 23.7 | 37.6/0.00 | 25.5 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 12.6 Cr. | 12.2 | 23.4/12.0 | 140 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 125 Cr. | 66.8 | 98.7/51.4 | 27.2 | 16.1 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 22.3 Cr. | 4.13 | 7.73/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 28,929.00 Cr | 869.53 | 70.99 | 95.14 | 0.30% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 503 | 534 | 489 | 491 | 541 | 601 | 539 | 545 | 602 | 660 | 597 | 603 | 670 |
| Expenses | 385 | 390 | 376 | 375 | 395 | 424 | 398 | 401 | 432 | 458 | 443 | 434 | 478 |
| Operating Profit | 118 | 144 | 113 | 116 | 146 | 178 | 141 | 145 | 170 | 202 | 154 | 169 | 192 |
| OPM % | 23% | 27% | 23% | 24% | 27% | 30% | 26% | 27% | 28% | 31% | 26% | 28% | 29% |
| Other Income | 8 | 9 | 10 | 14 | 14 | 18 | 18 | 18 | 21 | 22 | 25 | 26 | 28 |
| Interest | 8 | 11 | 9 | 9 | 8 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 |
| Depreciation | 36 | 39 | 38 | 38 | 35 | 36 | 36 | 37 | 35 | 35 | 36 | 36 | 35 |
| Profit before tax | 81 | 103 | 76 | 83 | 118 | 152 | 116 | 120 | 150 | 183 | 138 | 153 | 181 |
| Tax % | 28% | 30% | 30% | 32% | 29% | 27% | 29% | 28% | 28% | 29% | 29% | -1% | 26% |
| Net Profit | 58 | 72 | 54 | 57 | 84 | 111 | 82 | 86 | 108 | 131 | 98 | 156 | 134 |
| EPS in Rs | 6.92 | 8.60 | 6.33 | 6.80 | 9.90 | 13.09 | 9.74 | 10.12 | 12.75 | 15.46 | 11.57 | 18.52 | 15.80 |
Last Updated: August 1, 2025, 10:00 pm
Below is a detailed analysis of the quarterly data for Dr Lal Pathlabs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 670.00 Cr.. The value appears strong and on an upward trend. It has increased from 603.00 Cr. (Mar 2025) to 670.00 Cr., marking an increase of 67.00 Cr..
- For Expenses, as of Jun 2025, the value is 478.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 434.00 Cr. (Mar 2025) to 478.00 Cr., marking an increase of 44.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 192.00 Cr.. The value appears strong and on an upward trend. It has increased from 169.00 Cr. (Mar 2025) to 192.00 Cr., marking an increase of 23.00 Cr..
- For OPM %, as of Jun 2025, the value is 29.00%. The value appears strong and on an upward trend. It has increased from 28.00% (Mar 2025) to 29.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Mar 2025) to 28.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Depreciation, as of Jun 2025, the value is 35.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 36.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 181.00 Cr.. The value appears strong and on an upward trend. It has increased from 153.00 Cr. (Mar 2025) to 181.00 Cr., marking an increase of 28.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from -1.00% (Mar 2025) to 26.00%, marking an increase of 27.00%.
- For Net Profit, as of Jun 2025, the value is 134.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2025) to 134.00 Cr., marking a decrease of 22.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 15.80. The value appears to be declining and may need further review. It has decreased from 18.52 (Mar 2025) to 15.80, marking a decrease of 2.72.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:25 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 558 | 660 | 791 | 912 | 1,057 | 1,203 | 1,330 | 1,581 | 2,087 | 2,017 | 2,227 | 2,461 | 2,529 |
| Expenses | 419 | 504 | 582 | 675 | 793 | 910 | 987 | 1,145 | 1,526 | 1,527 | 1,617 | 1,764 | 1,812 |
| Operating Profit | 139 | 156 | 210 | 238 | 264 | 294 | 344 | 436 | 561 | 490 | 609 | 698 | 718 |
| OPM % | 25% | 24% | 26% | 26% | 25% | 24% | 26% | 28% | 27% | 24% | 27% | 28% | 28% |
| Other Income | 8 | 12 | 20 | 27 | 31 | 46 | 55 | 51 | 52 | 42 | 69 | 91 | 101 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 15 | 16 | 30 | 38 | 29 | 22 | 21 |
| Depreciation | 27 | 28 | 28 | 28 | 33 | 38 | 73 | 77 | 108 | 150 | 144 | 142 | 142 |
| Profit before tax | 119 | 140 | 201 | 237 | 261 | 301 | 310 | 394 | 475 | 344 | 505 | 625 | 656 |
| Tax % | 33% | 31% | 34% | 34% | 34% | 33% | 27% | 25% | 26% | 30% | 28% | 21% | |
| Net Profit | 80 | 96 | 133 | 156 | 172 | 200 | 228 | 296 | 350 | 241 | 362 | 492 | 518 |
| EPS in Rs | 148.27 | 17.51 | 15.99 | 18.61 | 20.49 | 23.90 | 27.11 | 34.99 | 41.37 | 28.65 | 42.85 | 58.28 | 61.35 |
| Dividend Payout % | 7% | 9% | 15% | 16% | 22% | 25% | 44% | 57% | 29% | 42% | 56% | -0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 20.00% | 38.54% | 17.29% | 10.26% | 16.28% | 14.00% | 29.82% | 18.24% | -31.14% | 50.21% | 35.91% |
| Change in YoY Net Profit Growth (%) | 0.00% | 18.54% | -21.25% | -7.04% | 6.02% | -2.28% | 15.82% | -11.58% | -49.39% | 81.35% | -14.30% |
Dr Lal Pathlabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 13% |
| 3 Years: | 6% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 17% |
| 3 Years: | 12% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 11% |
| 1 Year: | -3% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 22% |
| 3 Years: | 20% |
| Last Year: | 24% |
Last Updated: September 5, 2025, 3:10 am
Balance Sheet
Last Updated: June 16, 2025, 12:13 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 54 | 55 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 |
| Reserves | 151 | 260 | 425 | 512 | 705 | 862 | 949 | 1,162 | 1,418 | 1,583 | 1,766 | 2,089 |
| Borrowings | 28 | 27 | 0 | 0 | 0 | 0 | 0 | 150 | 533 | 420 | 247 | 157 |
| Other Liabilities | 119 | 134 | 118 | 95 | 128 | 145 | 341 | 265 | 309 | 297 | 357 | 383 |
| Total Liabilities | 352 | 475 | 625 | 690 | 916 | 1,091 | 1,374 | 1,661 | 2,343 | 2,383 | 2,454 | 2,713 |
| Fixed Assets | 140 | 150 | 166 | 152 | 208 | 209 | 413 | 447 | 1,369 | 1,305 | 1,228 | 1,168 |
| CWIP | 0 | 1 | 4 | 18 | 10 | 3 | 11 | 10 | 15 | 5 | 6 | 3 |
| Investments | 9 | 38 | 64 | 106 | 145 | 185 | 164 | 59 | 65 | 150 | 114 | 327 |
| Other Assets | 203 | 286 | 391 | 414 | 554 | 694 | 786 | 1,144 | 893 | 923 | 1,107 | 1,215 |
| Total Assets | 352 | 475 | 625 | 690 | 916 | 1,091 | 1,374 | 1,661 | 2,343 | 2,383 | 2,454 | 2,713 |
Below is a detailed analysis of the balance sheet data for Dr Lal Pathlabs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 83.00 Cr. (Mar 2024) to 84.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,089.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,766.00 Cr. (Mar 2024) to 2,089.00 Cr., marking an increase of 323.00 Cr..
- For Borrowings, as of Mar 2025, the value is 157.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 247.00 Cr. (Mar 2024) to 157.00 Cr., marking a decrease of 90.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 383.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 357.00 Cr. (Mar 2024) to 383.00 Cr., marking an increase of 26.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,713.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,454.00 Cr. (Mar 2024) to 2,713.00 Cr., marking an increase of 259.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,168.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,228.00 Cr. (Mar 2024) to 1,168.00 Cr., marking a decrease of 60.00 Cr..
- For CWIP, as of Mar 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 3.00 Cr..
- For Investments, as of Mar 2025, the value is 327.00 Cr.. The value appears strong and on an upward trend. It has increased from 114.00 Cr. (Mar 2024) to 327.00 Cr., marking an increase of 213.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,215.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,107.00 Cr. (Mar 2024) to 1,215.00 Cr., marking an increase of 108.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,713.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,454.00 Cr. (Mar 2024) to 2,713.00 Cr., marking an increase of 259.00 Cr..
Notably, the Reserves (2,089.00 Cr.) exceed the Borrowings (157.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 111.00 | 129.00 | 210.00 | 238.00 | 264.00 | 294.00 | 344.00 | 286.00 | 28.00 | 70.00 | 362.00 | 541.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16 | 17 | 17 | 17 | 14 | 16 | 14 | 15 | 15 | 13 | 13 | 13 |
| Inventory Days | 37 | 31 | 33 | 44 | 40 | 70 | 39 | 38 | 28 | 30 | 27 | |
| Days Payable | 90 | 89 | 97 | 106 | 111 | 144 | 132 | 107 | 127 | 151 | 151 | |
| Cash Conversion Cycle | 16 | -35 | -42 | -47 | -47 | -55 | -60 | -78 | -54 | -87 | -108 | -110 |
| Working Capital Days | -26 | -9 | 27 | 19 | 17 | 0 | -19 | -17 | -54 | -56 | -46 | -30 |
| ROCE % | 60% | 48% | 47% | 43% | 38% | 35% | 32% | 33% | 29% | 18% | 25% | 29% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| UTI Flexi Cap Fund | 1,517,723 | 1.68 | 401.87 | 1,517,723 | 2025-04-22 17:25:37 | 0% |
| HDFC Flexi Cap Fund - Regular Plan | 1,192,210 | 0.58 | 315.68 | 1,192,210 | 2025-04-22 17:25:37 | 0% |
| SBI Large & Midcap Fund | 650,000 | 0.73 | 172.11 | 650,000 | 2025-04-22 03:10:34 | 0% |
| HDFC ELSS Tax Saver Fund | 539,800 | 0.97 | 142.93 | 539,800 | 2025-04-22 03:10:34 | 0% |
| UTI Mid Cap Fund | 529,730 | 1.31 | 140.26 | 529,730 | 2025-04-22 03:10:34 | 0% |
| Nippon India Pharma Fund | 425,000 | 1.57 | 112.53 | 425,000 | 2025-04-22 03:10:34 | 0% |
| PGIM India Midcap Opportunities Fund | 388,808 | 1.02 | 102.95 | 388,808 | 2025-04-22 17:25:37 | 0% |
| HDFC Hybrid Equity Fund - Regular Plan | 242,957 | 0.28 | 64.33 | 242,957 | 2025-04-22 03:10:34 | 0% |
| Edelweiss Arbitrage Fund | 193,800 | 0.44 | 51.32 | 193,800 | 2025-04-22 03:10:34 | 0% |
| UTI Small Cap Fund | 158,465 | 1.11 | 41.96 | 158,465 | 2025-04-22 03:10:34 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 58.48 | 43.05 | 28.82 | 41.70 | 35.33 |
| Diluted EPS (Rs.) | 58.40 | 42.98 | 28.74 | 41.70 | 35.25 |
| Cash EPS (Rs.) | 75.86 | 60.60 | 46.93 | 55.00 | 44.83 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 259.92 | 225.85 | 203.86 | 185.20 | 153.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 259.92 | 225.85 | 203.86 | 185.20 | 153.10 |
| Revenue From Operations / Share (Rs.) | 294.45 | 266.73 | 241.93 | 250.45 | 189.72 |
| PBDIT / Share (Rs.) | 94.39 | 81.27 | 63.76 | 73.58 | 58.51 |
| PBIT / Share (Rs.) | 77.41 | 64.06 | 45.74 | 60.61 | 49.24 |
| PBT / Share (Rs.) | 74.74 | 60.55 | 41.24 | 56.99 | 47.32 |
| Net Profit / Share (Rs.) | 58.89 | 43.40 | 28.92 | 42.03 | 35.57 |
| NP After MI And SOA / Share (Rs.) | 58.27 | 42.85 | 28.65 | 41.37 | 34.99 |
| PBDIT Margin (%) | 32.05 | 30.46 | 26.35 | 29.37 | 30.83 |
| PBIT Margin (%) | 26.29 | 24.01 | 18.90 | 24.20 | 25.95 |
| PBT Margin (%) | 25.38 | 22.70 | 17.04 | 22.75 | 24.94 |
| Net Profit Margin (%) | 19.99 | 16.27 | 11.95 | 16.78 | 18.74 |
| NP After MI And SOA Margin (%) | 19.79 | 16.06 | 11.84 | 16.51 | 18.44 |
| Return on Networth / Equity (%) | 22.42 | 19.34 | 14.33 | 22.86 | 23.42 |
| Return on Capital Employeed (%) | 27.95 | 26.86 | 19.90 | 27.25 | 29.58 |
| Return On Assets (%) | 17.93 | 14.56 | 10.01 | 14.65 | 17.55 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.05 | 0.11 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.04 | 0.14 | 0.22 | 0.00 |
| Asset Turnover Ratio (%) | 0.95 | 0.91 | 0.85 | 0.96 | 1.01 |
| Current Ratio (X) | 3.39 | 2.42 | 2.07 | 1.75 | 4.18 |
| Quick Ratio (X) | 3.30 | 2.34 | 2.00 | 1.65 | 4.02 |
| Dividend Payout Ratio (NP) (%) | 41.03 | 55.76 | 41.62 | 33.55 | 33.98 |
| Dividend Payout Ratio (CP) (%) | 31.77 | 39.78 | 25.55 | 25.54 | 26.87 |
| Earning Retention Ratio (%) | 58.97 | 44.24 | 58.38 | 66.45 | 66.02 |
| Cash Earning Retention Ratio (%) | 68.23 | 60.22 | 74.45 | 74.46 | 73.13 |
| Interest Coverage Ratio (X) | 35.37 | 23.11 | 14.16 | 20.32 | 30.47 |
| Interest Coverage Ratio (Post Tax) (X) | 23.07 | 13.34 | 7.42 | 12.61 | 19.53 |
| Enterprise Value (Cr.) | 19910.02 | 18177.25 | 14843.34 | 21493.23 | 21670.29 |
| EV / Net Operating Revenue (X) | 8.09 | 8.16 | 7.36 | 10.30 | 13.70 |
| EV / EBITDA (X) | 25.23 | 26.79 | 27.92 | 35.05 | 44.44 |
| MarketCap / Net Operating Revenue (X) | 8.42 | 8.48 | 7.56 | 10.41 | 14.27 |
| Retention Ratios (%) | 58.96 | 44.23 | 58.37 | 66.44 | 66.01 |
| Price / BV (X) | 9.53 | 10.21 | 9.15 | 14.41 | 18.12 |
| Price / Net Operating Revenue (X) | 8.42 | 8.48 | 7.56 | 10.41 | 14.27 |
| EarningsYield | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Dr Lal Pathlabs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 58.48. This value is within the healthy range. It has increased from 43.05 (Mar 24) to 58.48, marking an increase of 15.43.
- For Diluted EPS (Rs.), as of Mar 25, the value is 58.40. This value is within the healthy range. It has increased from 42.98 (Mar 24) to 58.40, marking an increase of 15.42.
- For Cash EPS (Rs.), as of Mar 25, the value is 75.86. This value is within the healthy range. It has increased from 60.60 (Mar 24) to 75.86, marking an increase of 15.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 259.92. It has increased from 225.85 (Mar 24) to 259.92, marking an increase of 34.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 259.92. It has increased from 225.85 (Mar 24) to 259.92, marking an increase of 34.07.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 294.45. It has increased from 266.73 (Mar 24) to 294.45, marking an increase of 27.72.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 81.27 (Mar 24) to 94.39, marking an increase of 13.12.
- For PBIT / Share (Rs.), as of Mar 25, the value is 77.41. This value is within the healthy range. It has increased from 64.06 (Mar 24) to 77.41, marking an increase of 13.35.
- For PBT / Share (Rs.), as of Mar 25, the value is 74.74. This value is within the healthy range. It has increased from 60.55 (Mar 24) to 74.74, marking an increase of 14.19.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 58.89. This value is within the healthy range. It has increased from 43.40 (Mar 24) to 58.89, marking an increase of 15.49.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 58.27. This value is within the healthy range. It has increased from 42.85 (Mar 24) to 58.27, marking an increase of 15.42.
- For PBDIT Margin (%), as of Mar 25, the value is 32.05. This value is within the healthy range. It has increased from 30.46 (Mar 24) to 32.05, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 26.29. This value exceeds the healthy maximum of 20. It has increased from 24.01 (Mar 24) to 26.29, marking an increase of 2.28.
- For PBT Margin (%), as of Mar 25, the value is 25.38. This value is within the healthy range. It has increased from 22.70 (Mar 24) to 25.38, marking an increase of 2.68.
- For Net Profit Margin (%), as of Mar 25, the value is 19.99. This value exceeds the healthy maximum of 10. It has increased from 16.27 (Mar 24) to 19.99, marking an increase of 3.72.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 19.79. This value is within the healthy range. It has increased from 16.06 (Mar 24) to 19.79, marking an increase of 3.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is 22.42. This value is within the healthy range. It has increased from 19.34 (Mar 24) to 22.42, marking an increase of 3.08.
- For Return on Capital Employeed (%), as of Mar 25, the value is 27.95. This value is within the healthy range. It has increased from 26.86 (Mar 24) to 27.95, marking an increase of 1.09.
- For Return On Assets (%), as of Mar 25, the value is 17.93. This value is within the healthy range. It has increased from 14.56 (Mar 24) to 17.93, marking an increase of 3.37.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.00, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.95. It has increased from 0.91 (Mar 24) to 0.95, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.39, marking an increase of 0.97.
- For Quick Ratio (X), as of Mar 25, the value is 3.30. This value exceeds the healthy maximum of 2. It has increased from 2.34 (Mar 24) to 3.30, marking an increase of 0.96.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 41.03. This value is within the healthy range. It has decreased from 55.76 (Mar 24) to 41.03, marking a decrease of 14.73.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 31.77. This value is within the healthy range. It has decreased from 39.78 (Mar 24) to 31.77, marking a decrease of 8.01.
- For Earning Retention Ratio (%), as of Mar 25, the value is 58.97. This value is within the healthy range. It has increased from 44.24 (Mar 24) to 58.97, marking an increase of 14.73.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 68.23. This value is within the healthy range. It has increased from 60.22 (Mar 24) to 68.23, marking an increase of 8.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.37. This value is within the healthy range. It has increased from 23.11 (Mar 24) to 35.37, marking an increase of 12.26.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.07. This value is within the healthy range. It has increased from 13.34 (Mar 24) to 23.07, marking an increase of 9.73.
- For Enterprise Value (Cr.), as of Mar 25, the value is 19,910.02. It has increased from 18,177.25 (Mar 24) to 19,910.02, marking an increase of 1,732.77.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.09. This value exceeds the healthy maximum of 3. It has decreased from 8.16 (Mar 24) to 8.09, marking a decrease of 0.07.
- For EV / EBITDA (X), as of Mar 25, the value is 25.23. This value exceeds the healthy maximum of 15. It has decreased from 26.79 (Mar 24) to 25.23, marking a decrease of 1.56.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.42. This value exceeds the healthy maximum of 3. It has decreased from 8.48 (Mar 24) to 8.42, marking a decrease of 0.06.
- For Retention Ratios (%), as of Mar 25, the value is 58.96. This value is within the healthy range. It has increased from 44.23 (Mar 24) to 58.96, marking an increase of 14.73.
- For Price / BV (X), as of Mar 25, the value is 9.53. This value exceeds the healthy maximum of 3. It has decreased from 10.21 (Mar 24) to 9.53, marking a decrease of 0.68.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.42. This value exceeds the healthy maximum of 3. It has decreased from 8.48 (Mar 24) to 8.42, marking a decrease of 0.06.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lal Pathlabs Ltd:
- Net Profit Margin: 19.99%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 27.95% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 22.42% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.07
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 51 (Industry average Stock P/E: 70.99)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.99%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Block E, New Delhi Delhi 110085 | cs@lalpathlabs.com https://www.lalpathlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Brig.(Hony) Dr. Arvind Lal | Executive Chairman |
| Dr. Vandana Lal | Whole Time Director |
| Dr. Archana Lal Erdmann | Non Executive Director |
| Mr. Rahul Sharma | Non Executive Director |
| Mr. Arun Duggal | Independent Director |
| Mr. Gurinder Singh Kalra | Independent Director |
| Mr. Rajit Mehta | Independent Director |
| Mrs. Somya Satsangi | Independent Director |
| Mr. Rohit Bhasin | Independent Director |
FAQ
What is the intrinsic value of Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd's intrinsic value (as of 03 November 2025) is 2596.82 which is 20.22% lower the current market price of 3,255.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 27,255 Cr. market cap, FY2025-2026 high/low of 3,543/2,294, reserves of ₹2,089 Cr, and liabilities of 2,713 Cr.
What is the Market Cap of Dr Lal Pathlabs Ltd?
The Market Cap of Dr Lal Pathlabs Ltd is 27,255 Cr..
What is the current Stock Price of Dr Lal Pathlabs Ltd as on 03 November 2025?
The current stock price of Dr Lal Pathlabs Ltd as on 03 November 2025 is 3,255.
What is the High / Low of Dr Lal Pathlabs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dr Lal Pathlabs Ltd stocks is 3,543/2,294.
What is the Stock P/E of Dr Lal Pathlabs Ltd?
The Stock P/E of Dr Lal Pathlabs Ltd is 51.0.
What is the Book Value of Dr Lal Pathlabs Ltd?
The Book Value of Dr Lal Pathlabs Ltd is 260.
What is the Dividend Yield of Dr Lal Pathlabs Ltd?
The Dividend Yield of Dr Lal Pathlabs Ltd is 0.74 %.
What is the ROCE of Dr Lal Pathlabs Ltd?
The ROCE of Dr Lal Pathlabs Ltd is 28.9 %.
What is the ROE of Dr Lal Pathlabs Ltd?
The ROE of Dr Lal Pathlabs Ltd is 24.3 %.
What is the Face Value of Dr Lal Pathlabs Ltd?
The Face Value of Dr Lal Pathlabs Ltd is 10.0.